Back to overview

Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord.

Type of publication Peer-reviewed
Publikationsform Original article (peer-reviewed)
Author Hepatitis C- working group for COHERE in Eurocoord, Smit Colette, Arends Joop, Peters Lars, Montforte Antonella d'Arminio, Dabis Francois, Zangerle Robert, Daikos George, Mussini Christina, Mallolas Josep, de Wit Stephane, Zinkernagel Annelies, Cosin Jaime, Chene Genevieve, Raben Dorthe, Rockstroh Jürgen,
Project Swiss HIV Cohort Study (SHCS)
Show all

Original article (peer-reviewed)

Journal BMC infectious diseases
Volume (Issue) 15
Page(s) 498 - 498
Title of proceedings BMC infectious diseases
DOI 10.1186/s12879-015-1224-1

Open Access

Type of Open Access Publisher (Gold Open Access)


Contradicting results on the effect of abacavir (ABC) on hepatitis C virus (HCV) treatment responses in HIV/HCV co-infected patients have been reported. We evaluated the influence of ABC on the response to pegylated interferon (pegIFN) and ribavirin (RBV)-containing HCV treatment in HIV/HCV co-infected patients in a large European cohort collaboration, including data from different European countries. HIV/HCV co-infected patients were included if they were aged ≥16 years, received pegIFN alfa-2a or 2b and RBV combination treatment and were enrolled in the COHERE cohort collaboration. Logistic regression was used to evaluate the impact of abacavir on achieving a sustained virologic response (SVR) to HCV treatment. In total 1309 HIV/HCV co-infected patients who had received HCV therapy were included, of whom 490 (37 %) had achieved an SVR. No statistically significant difference was seen for patients using ABC-containing regimens compared to patients using an emtricitabine + tenofovir (FTC + TDF)-containing backbone, which was the most frequently used backbone. In the multivariate analyses, patients using a protease inhibitor (PI)-boosted regimen were less likely to achieve an SVR compared to patients using a non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based regimen (OR: 0.61, 95 % CI: 0.41-0.91). The backbone combinations zidovudine&lamivudine (AZT + 3TC) and stavudine&lamivudine (d4t + 3TC) were associated with lower SRV rates (0.45 (0.24-0.82) and 0.46 (0.22-0.96), respectively). The results of this large European cohort study validate that SVR rates are generally not affected by ABC. Use of d4T or AZT as part of the HIV treatment regimen was associated with a lower likelihood of achieving an SVR.